Soumit Roy
Stock Analyst at Jones Trading
(2.87)
# 1,726
Out of 5,042 analysts
43
Total ratings
31.25%
Success rate
5.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVXL Anavex Life Sciences | Downgrades: Hold | n/a | $8.62 | - | 1 | Oct 24, 2025 | |
| CGON CG Oncology | Initiates: Buy | $50 | $43.67 | +14.50% | 1 | Sep 8, 2025 | |
| TARA Protara Therapeutics | Initiates: Buy | $21 | $5.10 | +311.76% | 1 | May 22, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $40 | $18.59 | +115.17% | 1 | May 20, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Buy | $36 → $27 | $20.61 | +31.00% | 2 | May 16, 2025 | |
| ACRV Acrivon Therapeutics | Downgrades: Hold | n/a | $2.07 | - | 2 | May 16, 2025 | |
| ONCY Oncolytics Biotech | Downgrades: Hold | n/a | $1.20 | - | 2 | May 16, 2025 | |
| MURA Mural Oncology | Downgrades: Hold | n/a | $2.09 | - | 2 | Mar 25, 2025 | |
| CRVO CervoMed | Upgrades: Buy | $15 | $7.07 | +112.16% | 3 | Mar 13, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $10 | $4.85 | +106.19% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $34 | $27.96 | +21.60% | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $2.14 | +1,582.24% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $3.32 | +863.86% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $9.70 | -7.22% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $13.10 | +29.77% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $3.72 | +249.46% | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $4 | $0.89 | +349.44% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.78 | - | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $6.00 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $7.76 | +235.05% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $24.90 | +181.12% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $81.57 | -87.74% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.76 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $14.78 | +441.27% | 1 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.54 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $3.92 | +8,063.27% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $6.72 | +11,953.57% | 1 | Feb 24, 2021 |
Anavex Life Sciences
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $8.62
Upside: -
CG Oncology
Sep 8, 2025
Initiates: Buy
Price Target: $50
Current: $43.67
Upside: +14.50%
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $5.10
Upside: +311.76%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $18.59
Upside: +115.17%
Enliven Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $20.61
Upside: +31.00%
Acrivon Therapeutics
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.07
Upside: -
Oncolytics Biotech
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.20
Upside: -
Mural Oncology
Mar 25, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.09
Upside: -
CervoMed
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $7.07
Upside: +112.16%
Nuvation Bio
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $4.85
Upside: +106.19%
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $27.96
Upside: +21.60%
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $2.14
Upside: +1,582.24%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $3.32
Upside: +863.86%
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $9.70
Upside: -7.22%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $13.10
Upside: +29.77%
Sep 17, 2024
Initiates: Buy
Price Target: $13
Current: $3.72
Upside: +249.46%
Sep 11, 2024
Maintains: Buy
Price Target: $6 → $4
Current: $0.89
Upside: +349.44%
Jul 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.78
Upside: -
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $6.00
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $7.76
Upside: +235.05%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $24.90
Upside: +181.12%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $81.57
Upside: -87.74%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $5.76
Upside: -
Apr 19, 2023
Initiates: Buy
Price Target: $80
Current: $14.78
Upside: +441.27%
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.54
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $3.92
Upside: +8,063.27%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $6.72
Upside: +11,953.57%